Drug Cocktail

DRUG7 trials

Sponsors

Hoffmann-La Roche, Aragon Pharmaceuticals, Inc., Eli Lilly and Company, H. Lundbeck A/S, Washington State University

Conditions

HealthyInteractionMalignant MelanomaNeoplasm MetastasisProstatic Neoplasms, Castration-ResistantPsoriasis

Early Phase 1

Evaluating the Pharmacokinetics of Oregano and Potential Oregano-drug Interactions Using a Drug Cocktail Approach

RecruitingNCT06693960

Washington State UniversityInteraction

Start: 2024-09-26End: 2025-12-31Target: 16Updated: 2024-11-26

Phase 1

A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma

CompletedNCT01001299

Hoffmann-La RocheMalignant Melanoma

Start: 2009-11-30End: 2012-02-29Updated: 2017-08-15

A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer

Active, not recruitingNCT02592317

Aragon Pharmaceuticals, Inc.Prostatic Neoplasms, Castration-Resistant

Start: 2016-02-12End: 2027-12-31Updated: 2026-03-13

A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body

CompletedNCT02688088

Eli Lilly and CompanyNeoplasm Metastasis

Start: 2016-03-08End: 2021-01-06Updated: 2022-10-18

A Study of Ixekizumab in Participants With Plaque Psoriasis

CompletedNCT02993471

Eli Lilly and CompanyPsoriasis

Start: 2016-12-22End: 2017-11-21Updated: 2019-03-12

A Study of Mirikizumab in Participants With Plaque Psoriasis

CompletedNCT03718884

Eli Lilly and CompanyPsoriasis

Start: 2018-10-23End: 2019-10-28Updated: 2024-01-29

Effects of Repeated Doses of Foliglurax on Drug Metabolizing Enzymes in Healthy Subjects

CompletedNCT04275115

H. Lundbeck A/SHealthy

Start: 2020-02-10End: 2020-04-03Updated: 2020-04-24

Related Papers

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.

2012-01-01786 citations